<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04011449</url>
  </required_header>
  <id_info>
    <org_study_id>NEUR-2019-27724</org_study_id>
    <nct_id>NCT04011449</nct_id>
  </id_info>
  <brief_title>State-dependent Pathophysiological Oscillations in Parkinson's Disease and Treatment With DBS Using the Medtronic RC+S</brief_title>
  <official_title>State-dependent Pathophysiological Oscillations in Parkinson's Disease and Treatment With DBS Using the Medtronic RC+S</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objectives.&#xD;
&#xD;
      The ability of the RC+S to record Local Field Potentials (LFP's) is novel in Deep Brain&#xD;
      Stimulation (DBS) technology. The primary goals of this project are to use this function of&#xD;
      the RC+S to characterize:&#xD;
&#xD;
        1. The state- and target-dependency of neuronal oscillations in the subthalamic nucleus&#xD;
           (STN), internal globus pallidus (GPi) or external globus pallidus (GPe) of patients with&#xD;
           PD,&#xD;
&#xD;
        2. How these oscillations are altered by levodopa,&#xD;
&#xD;
        3. The effects of unilateral standard clinical isochronal (e.g. 140 Hz) GPi-, GPe-, and&#xD;
           STN-DBS on oscillatory activity and its relationship to the presence and severity of&#xD;
           parkinsonian motor signs.&#xD;
&#xD;
      These experiments will leverage the capacity to record LFPs from macroelectrodes implanted in&#xD;
      either the GPi/GPe or STN using the Medtronic RC+S DBS system. The long-term goal for this&#xD;
      project is to develop closed-loop methods for DBS that are state (resting vs. movement) and&#xD;
      movement-phase appropriate.&#xD;
&#xD;
      Secondary objectives.&#xD;
&#xD;
      In addition to establishing the relationship between neural oscillations in the STN, GPi and&#xD;
      GPe to clinical and quantitative measures of akinesia, bradykinesia, tremor and rigidity,&#xD;
      this project will also examine the relationship of neural oscillations to:&#xD;
&#xD;
        1. Levodopa-resistant motor features such as postural instability and gait (including&#xD;
           freezing of gait),&#xD;
&#xD;
        2. Response inhibition and impulse control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Olympus Research System (RC+S) is an implantable pulse generator (IPG) designed to&#xD;
      deliver deep brain stimulation (DBS) like a standard clinical neurostimulator, but which&#xD;
      allows recordings of local field potential (LFP) activity from the implanted DBS lead.&#xD;
&#xD;
      LFPs are composite electrical signals generated by the brain. They are conventionally divided&#xD;
      into frequency bands, as follows: 0-3 Hz (delta), 4-7 Hz (theta), 8-12 Hz (alpha), 13-30 Hz&#xD;
      (beta), 31-200 Hz (gamma), and &gt;200 Hz (high frequency). The instantaneous amplitude and&#xD;
      power of the LFP recordings are believed to represent the degree of synchronization among&#xD;
      neurons surrounding the electrode. A transient increase in power in a particular band, in&#xD;
      response to a behavioral event, is called an event-related synchronization (ERS), while a&#xD;
      transient decrease in power is called event-related desynchronization (ERD). ERD and ERS are&#xD;
      typically calculated by averaging the power across time segments and comparing this average&#xD;
      to a reference epoch.&#xD;
&#xD;
      Research staff at the University of Minnesota will follow FDA guidelines for software&#xD;
      development for the RC+S.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Passive and Active Rigidity Quantification</measure>
    <time_frame>6-months</time_frame>
    <description>Peak resistive torque integral of resistive torque over the pronation and supination Range of Motion (ROM)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ballistic Elbow Flexion to a Target: Peak Velocity</measure>
    <time_frame>6-months</time_frame>
    <description>Peak velocity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ballistic Elbow Flexion to a Target: Stop Reaction Time</measure>
    <time_frame>6-months</time_frame>
    <description>Stop reaction time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rapid Alternating Pronation-Supination Movements: RMS</measure>
    <time_frame>6-months</time_frame>
    <description>Root Mean Square (RMS)-Displacement RMS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rapid Alternating Pronation-Supination Movements: Freezing Episodes Duration</measure>
    <time_frame>6-months</time_frame>
    <description>Duration of hesitation or arrest (freezing) episodes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rapid Alternating Pronation-Supination Movements: Freezing Episodes Number</measure>
    <time_frame>6-months</time_frame>
    <description>Number of hesitation or arrest (freezing) episodes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gait: Step length</measure>
    <time_frame>6-months</time_frame>
    <description>Step length</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gait: Step Time</measure>
    <time_frame>6-months</time_frame>
    <description>Step time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gait: Double Support Time</measure>
    <time_frame>6-months</time_frame>
    <description>Double support time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gait: Obstacles</measure>
    <time_frame>6-months</time_frame>
    <description>Percentage of obstacles successfully avoided</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gait: Freezing Episodes Duration</measure>
    <time_frame>6-months</time_frame>
    <description>Duration of freezing episodes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gait: Freezing Episodes Number</measure>
    <time_frame>6-months</time_frame>
    <description>Number of freezing episodes</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Parkinson</condition>
  <arm_group>
    <arm_group_label>Device Implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of the Medtronic RC+S Deep Brain Stimulation (DBS) system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic RC+S DBS system</intervention_name>
    <description>Implantation of the Medtronic RC+S Deep Brain Stimulation (DBS) system</description>
    <arm_group_label>Device Implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of idiopathic PD.&#xD;
&#xD;
          -  Age 45-75 years&#xD;
&#xD;
          -  Demonstrated good response (â‰¥ 30%) to Sinemet or dopamine agonist medications as&#xD;
             assessed by total UPDRS III score (off and on meds)&#xD;
&#xD;
          -  Clinical plan for unilateral STN- or GPi-DBS surgery to treat their clinical motor&#xD;
             signs within the next four months&#xD;
&#xD;
          -  Written documentation of willingness to participate in the study per protocol as&#xD;
             evidenced by the informed consent process&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant medical disease that would increase the risk of developing pre-&#xD;
             or post-operative complications (e.g., major cardiac or pulmonary disease)&#xD;
&#xD;
          -  Evidence of secondary or atypical parkinsonism&#xD;
&#xD;
          -  Dementia as evidenced by impairment in two neuropsychological domains and impaired or&#xD;
             borderline neuropsychological function in one additional domain.&#xD;
&#xD;
          -  Unable to undergo MR imaging (e.g., due to incompatible implanted pacemaker)&#xD;
&#xD;
          -  Previous pallidotomy or DBS surgery&#xD;
&#xD;
          -  Women who are currently pregnant&#xD;
&#xD;
          -  MRI brain abnormalities that could indicate a neurological disorder other than&#xD;
             idiopathic Lewy body Parkinson's disease.&#xD;
&#xD;
          -  Subjects with severe or poorly controlled depression defined according to DSM-V&#xD;
             criteria and a scored on a validated depression assessment scale.&#xD;
&#xD;
          -  Epilepsy&#xD;
&#xD;
          -  Immunocompromised&#xD;
&#xD;
          -  Requires diathermy, electroconvulsive therapy (ECT) or transcranial magnetic&#xD;
             stimulation (TMS) to treat a chronic condition&#xD;
&#xD;
          -  Has an implanted electronic device such as a neurostimulator, cardiac pacemaker or&#xD;
             medication pump.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 10, 2019</study_first_submitted>
  <study_first_submitted_qc>July 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2019</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

